VisionHealth GmbH, a Garching, Germany-based provider of digital therapy support in inhalation therapy for the treatment of chronic respiratory diseases, closed a €1.5m financing round.
Backers included Dr. Thomas Ecker, the Vantage Value GmbH, a Family Office in Eching (Germany). Erwin J. Schimmer of Vantage Value will take a seat on VisionHealth’s board of directors.
The company will use the funds to conduct a health economic trial and complete the approval process of the Kata app by the German Federal Institute for Drugs and Medical Devices, BfArM, as a Digital Health Application within the framework of the German Digital Health Care Act (DVG), which will enable permanent reimbursement by German health insurance companies, to enter the market in Germany and generate revenue, via licensing Kata® to pharmaceutical and medtech companies.
Founded in 2017 by Dr. Sabine Haeussermann, CEO, VisionHealth is a digital therapy support company focused on respiratory diseases. In cooperation with research institutions and selected industry partners, medical experts and IT experts, VisionHealth develops digital health solutions enabling sustainable improvements in existing standard therapy for patients with chronic respiratory diseases.
The digital therapy app Kata is a medical device assisting patients with their inhalation therapy for respiratory diseases. The app optimizes the drug inhalation therapy of chronic lung diseases through digital support.